6-K Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â Â FORM 6-K Â Â REPORT OFFOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission file number: 001-41670 Â Â Apollomics Inc. (Exactname of registrant as specified in its charter) Â Â NotApplicable (Translation of registrantâ€™s name into English) 989 E. Hillsdale Blvd., Suite 220 Foster City, California 94404 (Address of principal executive office) Â Â Indicate by check mark whetherthe registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-Fâ€‚â˜’â€‚Form40-Fâ€‚â˜ Â Â Â On DecemberÂ 20, 2024, Apollomics Inc. (the â€œCompanyâ€) issued a press release announcingresults for its Phase 3 bridging trial of uproleselan in China. A copy of the press release is furnished hereto as Exhibit 99.1. The press release setforth in Exhibit 99.1 is being furnished with the Commission and shall not be deemed â€œfiledâ€ for purposes of SectionÂ 18 of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), or otherwise subject to theliabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the â€œSecurities Actâ€), or the Exchange Act. Notwithstanding the foregoing, the information in the press release is incorporated by reference into the Companyâ€™s registration statements under theSecurities Act, statements, including its registration statements on Form S-8 (File No.Â 333-272559), Form F-1 (File No.Â 333-272552) and Form F-3 (File Nos. 333-278430, 333-278431 and 333-279549), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished. Â ExhibitNo. Â Â Description 99.1 Â Â Press Release, dated DecemberÂ 20, 2024, entitled â€œApollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemiaâ€ SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by theundersigned thereunto duly authorized. Â Â Â Â Â Apollomics Inc. Date: DecemberÂ 20, 2024 Â Â By: Â /s/ Guo-Liang Yu Â Â Â Â Â Â Â Guo-Liang Yu, Ph.D. Chief ExecutiveOfficer Â Â 3 EX-99.1 Exhibit 99.1 Â Apollomics Announces Top-line Results for Phase 3 Bridging Trialof Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia FOSTER CITY, Calif. â€“ DecemberÂ 20, 2024 (GLOBAL NEWSWIRE) â€“ Apollomics Inc. (Nasdaq: APLM) (â€œApollomicsâ€ or theâ€œCompanyâ€), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistantcancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan. The Phase 3 trial was a randomized, double-blinded bridging trial to evaluate the safety and efficacy of uproleselan administered with chemotherapy versuschemotherapy alone in patients with relapsed or refractory acute myeloid leukemia. The primary endpoint was comparing overall survival (OS) in the uproleselan treatment arm versus the control arm. A total of 140 subjects were enrolled in the Phase 3trial and randomized 1:1 to receive either uproleselan with chemotherapy (n=69) or chemotherapy alone (n=71). The median OS in the uproleselan arm was 9.3 months (95% CI 6.1 â€“ 16.0 months) versus 14.3 months (95% CI 6.2 â€“ NA months) in thechemotherapy-only arm (p=0.48). Addition of uproleselan to chemotherapy was generally well tolerated, with a similar safety profile to the control arm. The incidence of serious adverse events was 43% in the uproleselan arm versus 39% in thechemotherapy-only arm. The most common serious adverse events in the uproleselan arm were decreased platelet count, infectious pneumonia, and sepsis. â€œWhile we are disappointed that uproleselan did not show a clinical benefit, the results were expected given that the global Phase 3 trial of uproleselanin a similar patient population by our partner, Glycomimetics, did not meet its primary endpoint earlier this year. Our regulatory and commercial strategy in China has always required a positive global Phase 3 trial, and therefore we are currentlywrapping up this program,â€ said Guo-Liang Yu, PhD, Chairman and CEO of Apollomics. â€œWe extend our thanks and gratitude to all the patients and their families, investigators and clinical team that supported the trial.â€ In August 2024, Apollomics announced the write-down of the intangible asset related to the upfront payment for the uproleselan program. Apollomics isconcluding the clinical trial and expects future expenses for the uproleselan program to be less than $500,000. The Company intends to submit the fullresults of this trial for presentation at a future medical conference. About Apollomics Inc. Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential tobe combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomicsâ€™ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently ina Phase 2 multicohort clinical trial in the United States and over 10 other countries. For more information, please visit www.apollomicsinc.com. Cautionary Statement Regarding Forward-Looking Statements This press release includes statements that constitute â€œforward-looking statementsâ€ within the meaning of the federal securities laws, includingSectionÂ 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and SectionÂ 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). All statements, other than statements of present orhistorical fact included in this press release, regarding the Companyâ€™s strategy, prospects, plans and objectives are forward-looking statements, including statements about the conclusion, expenses and results of the Phase 3 bridging trial. When used in this press release, the wordsâ€œcould,â€ â€œshould,â€ â€œwill,â€ â€œmay,â€ â€œbelieve,â€ â€œanticipate,â€ â€œintend,â€ â€œestimate,â€ â€œexpect,â€ â€œproject,â€ the negative of such terms and other similarexpressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on managementâ€™s current expectations and assumptions aboutfuture events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficultto predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i)Â the impact of any current or new government regulations in the United States and China affecting Apollomicsâ€™ operations and the continued listing of Apollomicsâ€™ securities; (ii)Â the inability to achieve successful clinicalresults or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomicsâ€™ oncology projects; (iii)Â the failure to commercialize product candidates and achieve market acceptance of suchproduct candidates; (iv)Â the failure to protect Apollomicsâ€™ intellectual property; (v)Â breaches in data security; (vi)Â the risk that Apollomics may not be able to develop and maintain effective internal controls;(vii)Â unfavorable changes to the regulatory environment; and (viii)Â those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended DecemberÂ 31, 2023, filed byApollomics Inc. with the U.S. Securities and Exchange Commission (â€œSECâ€) under the heading â€œRisk Factorsâ€ and the other documents filed, or to be filed, by the Company with

the SEC. Additional information concerning these andother factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SECâ€™s website atwww.sec.gov. Forward-looking statements speak only as of the date made by the Company. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changesin assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. Investor Contact: Eric Ribner LifeSci Advisors, LLC (646) 751-4363 eric@lifesciadvisors.com